Relations of Change in Plasma Levels of LDL‐C, Non‐HDL‐C and apoB With Risk Reduction From Statin Therapy: A Meta‐Analysis of Randomized Trials
暂无分享,去创建一个
R. Brook | C. Furberg | P. Lawler | J. de Graaf | K. Williams | A. Sniderman | P. Couture | G. Thanassoulis | Keying Ye
[1] L. Hedges,et al. Introduction to Meta‐Analysis , 2009, International Coaching Psychology Review.
[2] Jennifer G. Robinson,et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.
[3] C. Furberg,et al. The necessity for clinical reasoning in the era of evidence-based medicine. , 2013, Mayo Clinic proceedings.
[4] Robert Dufour,et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. , 2013, The Canadian journal of cardiology.
[5] Jennifer G. Robinson,et al. Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials. , 2012, The American journal of cardiology.
[6] J. de Graaf,et al. Phenotypes of hypertriglyceridemia caused by excess very-low-density lipoprotein. , 2012, Journal of clinical lipidology.
[7] Shah Ebrahim,et al. European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.
[8] C. Furberg,et al. Is lower and lower better and better? A re-evaluation of the evidence from the Cholesterol Treatment Trialists' Collaboration meta-analysis for low-density lipoprotein lowering. , 2012, Journal of clinical lipidology.
[9] R. Collins,et al. Lipids and Lipoproteins and Risk of Different Vascular Events in the MRC/BHF Heart Protection Study , 2012, Circulation.
[10] P. Toth. Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins: A Meta-analysis , 2012 .
[11] P. Ridker,et al. Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial. , 2012, Clinical chemistry.
[12] C. Furberg,et al. A Meta-Analysis of Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, and Apolipoprotein B as Markers of Cardiovascular Risk , 2011, Circulation. Cardiovascular quality and outcomes.
[13] R. Collins,et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.
[14] Børge G Nordestgaard,et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial , 2009, The Lancet.
[15] A. Sniderman. Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice. , 2008, Journal of clinical lipidology.
[16] F. Hu,et al. patient-oriented and epidemiological research Apolipoprotein B and non-high density lipoprotein cholesterol and the risk of coronary heart disease in Chinese , 2007 .
[17] Shah Ebrahim,et al. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts) , 2007 .
[18] J. Farmer. High-dose atorvastatin after stroke or transient ischemic attack. , 2007, Current atherosclerosis reports.
[19] M. Hennerici,et al. High-dose atorvastatin after stroke or transient ischemic attack. , 2006, The New England journal of medicine.
[20] A. Biggeri,et al. Effect of age on the association of non-high-density-lipoprotein cholesterol and apolipoprotein B with cardiovascular mortality in a Mediterranean population with type 2 diabetes: the Casale Monferrato study , 2006, Diabetologia.
[21] Nader Rifai,et al. Non–High-Density Lipoprotein Cholesterol and Apolipoprotein B in the Prediction of Coronary Heart Disease in Men , 2005, Circulation.
[22] J. Manson,et al. Multivariate Assessment of Lipid Parameters as Predictors of Coronary Heart Disease Among Postmenopausal Women: Potential Implications for Clinical Guidelines , 2004, Circulation.
[23] John H Fuller,et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.
[24] 曲东锋. Stroke Prevention by Aggressive Reduction in Cholesterol Levels , 2004 .
[25] AndrewJ. S. Coats. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.
[26] A. Keech,et al. Relationship Between Lipid Levels and Clinical Outcomes in the Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID) Trial: To What Extent Is the Reduction in Coronary Events With Pravastatin Explained by On-Study Lipid Levels? , 2002, Circulation.
[27] S. Yusuf. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .
[28] D R Shapiro,et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). , 2000, Circulation.
[29] G. Thorgeirsson,et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S) , 1998, Circulation.
[30] M. Carroll,et al. Apolipoprotein B and AI distributions in the United States, 1988-1991: results of the National Health and Nutrition Examination Survey III (NHANES III). , 1997, Clinical chemistry.
[31] Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. , 1997, The New England journal of medicine.